Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1
Recruiting
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-CellNon-Hodgkin Lymphoma, B-cellDiffuse Large B Cell LymphomaMCLCentral Nervous System LymphomaAcute Lymphoblastic Leukemia, in RelapseLymphoma, Follicular
- Interventions
- Biological: CD19/CD22-CAR T cells
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06213636
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath